Capecitabine

Sort by

Capecitabine EP impurity D

  • CAT NUMBER DCTI-C-3537
  • CAS NUMBER 910129-15-6
  • MOLECULAR FORMULA C15H22FN3O6
  • MOLECULAR WEIGHT 359.35

Capecitabine EP impurity E

  • CAT NUMBER DCTI-C-3536
  • CAS NUMBER 162204-30-0
  • MOLECULAR FORMULA C15H22FN3O6
  • MOLECULAR WEIGHT 359.35

Capecitabine Isomers Mixture

  • CAT NUMBER DCTI-C-3523
  • CAS NUMBER 910129-15-6(2-Methyl Analog) 162204-30-0(3-Methyl Analog)
  • MOLECULAR FORMULA C15H22FN3O6
  • MOLECULAR WEIGHT 359.35

General Information

Capecitabine Impurities and Capecitabine

Daicel Pharma offers high-quality Capecitabine impurities, Capecitabine EP impurity D, Capecitabine EP impurity E, and Capecitabine Isomers Mixture. They are vital for evaluating the quality, stability, and biological safety of Capecitabine. Furthermore, Daicel Pharma specializes in the custom synthesis of Capecitabine impurities and ensures their worldwide delivery.

Capecitabine [CAS: 154361-50-9] is an antineoplastic agent for cancer treatment. It belongs to the category of carbamate esters. It is a prodrug of 5’-deoxy-5-fluorouridine (5’-DFUR) and converted to 5-fluorouracil.

Capecitabine: Use and Commercial Availability

Capecitabine is a fluoropyrimidine carbamate, a type of antineoplastic agent. It treats patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. Capecitabine, marketed under the brand name Xeloda, is utilized as an antimetabolite in the treatment of colon cancer, breast cancer, and gastric cancer.

Capecitabine Structure and Mechanism of Action

Capecitabine Structure and Mechanism of Action
The chemical name of Capecitabine is 5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine. The chemical formula for Capecitabine is C15H22FN3O6, and its molecular weight is approximately 359.35g/mol.

Capecitabine activation is by tumor cells selectively to its cytotoxic moiety, 5-fluorouracil (5-FU). Further, 5-FU metabolizes to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).

Capecitabine Impurities and Synthesis

While synthesizing Capecitabine1, stringent protocols can uphold its purity and effectiveness. However, impurities may arise during the process, posing challenges to drug quality. Advanced purification methods such as chromatography and crystallization can mitigate impurities. Continuous vigilance and adherence to rigorous quality control measures are imperative to ensure the integrity of Capecitabine throughout its synthesis.

Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Capecitabine impurities, which includes Capecitabine EP impurity D, Capecitabine EP impurity E, and Capecitabine Isomers Mixture. The CoA is from a cGMP-compliant analytical facility and encompasses complete characterization data such as 1H NMR, 13C NMR2, IR, MASS, and HPLC purity. On request, we give additional data like 13C-DEPT and CHN. Daicel Pharma also prepares any unidentified Capecitabine impurity or degradation product. Furthermore, Daicel Pharma offers highly purified isotope-labeled standards of Capecitabine for bioanalytical research and BA/BE studies. We provide a complete characterization report upon delivery.

References
FAQ's

Frequently Asked Questions

Capecitabine impurities are minimized through careful selection of raw materials, optimization of synthetic routes, purification techniques, and stringent quality control measures.

Impurity profiling helps understand the nature and quantity of impurities in pharmaceuticals, which is crucial for the safety and efficacy of the drug.

Impurities can contribute to the degradation of Capecitabine over time, leading to reduced stability and shelf-life of the drug product.

Variations in impurity profiles between batches of Capecitabine can arise from differences in synthesis processes, raw materials, or storage conditions.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart